934536-10-4

Basic information

• Product Name: TERT-BUTYL 4-AMINO-3-FLUOROPIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-AMINO-3-FLUOROPIPERIDINE-1-CARBOXYLATE;4-AMino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 4-aMino-3-fluoro-, 1,1-diMethylethyl ester;1-Boc-3-fluoro-4-aMinopiperidine;4-AMino-1-Boc-3-fluoropiperidine;1-(tert-Butyloxycarbonyl)-3-fluoro-4-aminopiperidine;4-amino-3-fluoro-1-Piperidinecarboxylic acid tert-butyl ester;EOS-61547
• CAS NO: 934536-10-4
• Molecular Formula: C₁₀H₁₉FN₂O₂
• Molecular Weight: 218.27
• Mol File: 934536-10-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 285.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.88±0.40(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-AMINO-3-FLUOROPIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-AMINO-3-FLUOROPIPERIDINE-1-CARBOXYLATE(934536-10-4)
• EPA Substance Registry System: TERT-BUTYL 4-AMINO-3-FLUOROPIPERIDINE-1-CARBOXYLATE(934536-10-4)

Safety Data

• Hazardous Substances Data: 934536-10-4(Hazardous Substances Data)

Usage

Uses

1-(tert-Butyloxycarbonyl)-3-Fluoro-4-aminopiperidine is a reactant in the preparation of pharmaceutical compounds which are antagonists of CGRP (Calcitonin gene-related peptide) receptors and useful in the treatment of migraine.

Upstream product

• 110-86-1 pyridine 
• 1070896-84-2 tert-butyl 3-fluoro-4-((methylsulfonyl)oxy)piperidine-1-carboxylate 
• 373604-28-5 3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 
• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 934536-11-5 4-Benzyloxycarbonylamino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester 
• 1454284-94-6 tert-butyl 3-fluoro-4-[[4-[(imidazo[1,2-a]pyridine-6-carbonylamino)methyl]phenyl]sulfonylamino]piperidine-1-carboxylate 
• 211108-52-0 (3R,4R)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3S,4S)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 1033748-75-2 (3S,4R)-tert-butyl 4-(((benzyloxy)carbonyl)amino)-3-fluoropiperidine-1-carboxylate 
• 1351866-21-1 (3R,4S)-tert-butyl 4-(((benzyloxy)carbonyl)amino)-3-fluoropiperidine-1-carboxylate 
• 577691-56-6 (3S,4S)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 1260612-08-5 (3R,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 

Relevant articles and documents

PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES

Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them

The disclosure relates particularly to certain carboxamide, sulfonamide and amine compounds and pharmaceutical compositions thereof, and to methods of treating and ameliorating disorders and conditions related to the adiponectin pathway, sphingolipid metabolism, oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. In certain embodiments, the compounds have the structures (I-1), (2-I) and (3-I) in which the variables are as described herein.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.